Why scientists are racing to develop more COVID antivirals
A recent news article in Nature by Max Kozlov discusses the future for COVID-19 antivirals and their impact on the pandemic. Interviewees include leaders in SARS-CoV-2 and antiviral research; Tim Sheahan, a leading corona virologist at the University of North Carolina at Chapel Hill, Matt Hall, the director of the early translation branch at the US National Center for Advancing Translational Sciences (NCATS), and Carl Dieffenbach, director of the division of AIDS at the US National Institute of Allergy and Infectious Diseases (NIAID).
In this article, Cornell College of Veterinary Medicine, Baker Institute faculty member and virologist Luis Schang discussed the development and impact of combination therapies and the needs to identify and validate novel targets for antivirals to better deal with COVID-19 and be better prepared for future pandemic.
